Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Thermo Fisher Scientific and Newman-Lakka Institute to Collaborate

Published: Tuesday, June 25, 2013
Last Updated: Tuesday, June 25, 2013
Bookmark and Share
The collaboration will research diagnostic approaches for personalized cancer treatment.

Thermo Fisher Scientific Inc. and the Newman-Lakka Institute for Personalized Cancer Care at Floating Hospital for Children at Tufts Medical Center have announced an intended collaboration for research and development of new methods to detect and track circulating biomarkers in blood.

The collaboration will focus on applying Thermo Fisher’s latest ultra-sensitive liquid chromatography-mass spectrometry (LC-MS) instrumentation and technology to develop robust methods for identifying protein biomarkers for a variety of cancers, including breast and prostate cancer as well as tumor-associated blood vessel formation.

“Our challenge and hope is to change the current standard of care, and our collaboration with Thermo Fisher and access to its state-of-the-art instrumentation will accelerate our mission. We hope to be able to provide oncologists with a panel of biomarkers that sense microscopic levels of tumor cells with a simple blood test,” said Charles J. Newman, president of the Newman-Lakka Cancer Foundation.

Newman continued, “The goal is to develop diagnostic tools to make it possible for physicians to check off a panel of biomarkers when patients get regular checkups, so early detection of disease can facilitate effective treatment. Also, the goal is to enable oncologists to monitor the efficacy of treatment with a blood test, rather than waiting 2 months for an MRI and exposing the patients to additional harmful radiation.”

“We’re extremely pleased about this opportunity to collaborate with experts in the search for better cancer treatments,” said Mary Lopez, director of the Thermo Fisher Scientific Biomarkers Research Initiatives in Mass Spectrometry (BRIMS) center that is supporting the collaboration.

Lopez continued, “We anticipate great synergy between Newman-Lakka’s cancer research expertise and our own strength in applying mass spectrometry to biological research and the advancement of personalized medicine will give greater value to both organizations.”

An instrument will be installed at the Genesis Research Institute laboratory adjacent to the Newman Lakka Institute at Tufts Medical Center.

The collaboration’s advanced methods will be conducted at the BRIMS center in Cambridge, Mass., using Thermo Scientific’s triple quadrupole and high resolution accurate mass (HRAM) spectrometry instrumentation, coupled to mass spectrometry immunoassay (MSIA) technology and novel software workflows.

Thermo Fisher’s mass spectrometry instruments are for research use only. Not for use in diagnostic procedures.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Transcriptome Profiling Grants Launched
Request for proposal aims to identify promising research projects involving precious samples.
Monday, October 20, 2014
Thermo Fisher Scientific, GSK and Pfizer Collaboration
Thermo Fisher Scientific announces agreement with GlaxoSmithKline and Pfizer to develop oncology companion diagnostics using Next-Generation Sequencing (NGS.)
Thursday, September 25, 2014
Thermo Fisher, Cellectis Enter TAL Nucleases Licensing Agreement
Cellectis and Thermo Fisher Scientific announced that they have entered into a series of agreements covering the uses of TAL nucleases under the brand name TALEN™.
Thursday, June 05, 2014
Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos